INSMED Reports Material Agreements & Financial Condition

Ticker: INSM · Form: 8-K · Filed: 2024-02-22T00:00:00.000Z

Sentiment: mixed

Topics: material-agreement, corporate-change, financial-condition

TL;DR

**INSMED just dropped an 8-K about new and terminated material agreements, plus financial results, so watch for details!**

AI Summary

INSMED Incorporated filed an 8-K on February 22, 2024, reporting on an entry into a material definitive agreement, the termination of a material definitive agreement, and results of operations and financial condition. The filing indicates a significant corporate event, potentially impacting the company's financial outlook and strategic direction, though specific details of the agreements or financial results are not provided in the excerpt.

Why It Matters

This filing signals significant changes in INSMED's corporate agreements and financial standing, which could affect its future operations and investor confidence.

Risk Assessment

Risk Level: medium — The filing mentions both entry into and termination of material definitive agreements, indicating significant corporate changes that could have both positive and negative implications.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by INSMED Incorporated?

The 8-K filing by INSMED Incorporated on February 22, 2024, reports on the entry into a material definitive agreement, the termination of a material definitive agreement, and results of operations and financial condition.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 22, 2024.

What is the state of incorporation for INSMED Incorporated?

INSMED Incorporated is incorporated in Virginia.

What is the business address of INSMED Incorporated?

The business address of INSMED Incorporated is 700 US Highway 202/206, Bridgewater, New Jersey 08807.

What is the telephone number for INSMED Incorporated?

The telephone number for INSMED Incorporated is (908) 977-9900.

Filing Stats: 1,480 words · 6 min read · ~5 pages · Grade level 12.3 · Accepted 2024-02-22 07:58:04

Key Financial Figures

Filing Documents

01 – Entry into a Material Definitive Agreement

ITEM 1.01 – Entry into a Material Definitive Agreement. On February 22, 2024, Insmed Incorporated (the "Company") entered into a Sales Agreement (the "Agreement") with Leerink Partners LLC, as agent ("Leerink"), under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $500,000,000 (the "Shares") during the term of the Agreement through Leerink, acting as agent. The Company has filed a prospectus supplement relating to the offer and sale of the Shares pursuant to the Agreement. The Shares will be issued pursuant to the Company's previously filed and effective Registration Statement on Form S-3 (File No. 333-272088), which was initially filed with the Securities and Exchange Commission (the "SEC") and became automatically effective on May 19, 2023. The Company intends to use the net proceeds from the offering, if any, to fund activities related to the commercialization and development of ARIKAYCE, continued research and development of brensocatib as well as pre-commercial and, if approved, commercialization activities related to brensocatib, further research and development of treprostinil palmitil inhalation powder and any of our other research product candidates, and for other general corporate purposes, including business expansion activities. The Company is not obligated to sell any Shares pursuant to the Agreement. Subject to the terms and conditions of the Agreement, Leerink will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Select Market ("Nasdaq"), to sell Shares from time to time based upon the Company's instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. Under the Agreement, Leerink may sell Shares by any method permitted by law deemed to be an "at the mar

02 – Termination of a Material Definitive Agreement

ITEM 1.02 – Termination of a Material Definitive Agreement. As previously disclosed, on February 25, 2021, the Company entered into a Sales Agreement (the "Prior Agreement") with Leerink, under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $250,000,000 during the term of the Prior Agreement through Leerink, acting as agent. On February 22, 2024, in connection with entry into the Agreement described under Item 1.01 above, the Company and Leerink mutually agreed to terminate the Prior Agreement, which termination became effective on February 22, 2024. The Company is not subject to any termination penalties related to the termination of the Prior Agreement. A copy of the Prior Agreement was filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 25, 2021 (the "Prior Form 8-K"). The foregoing summary of the Prior Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Prior Agreement, a copy of which is filed as Exhibit 10.1 to the Prior Form 8-K.

02 – Results of Operations and Financial Condition

ITEM 2.02 – Results of Operations and Financial Condition. On February 22, 2024, Insmed Incorporated issued a press release regarding its financial results for the three months and fiscal year ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The information contained herein, including the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 , as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Financial Statements and Exhibits

ITEM 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Hunton Andrews Kurth LLP. 10.1 Sales Agreement, dated as of February 22, 2024, between Leerink Partners LLC and Insmed Incorporated. 23.1 Consent of Hunton Andrews Kurth LLP (included as part of Exhibit 5.1). 99.1 Press release issued by Insmed Incorporated on February 22, 2024. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 22, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing